CSIR-Indian Institute of Integrative Medicine

What CSIR-Indian Institute of Integrative Medicine does

CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM) is a government-owned national research laboratory headquartered in Jammu, India, operating under the Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India. The institute is the only CSIR lab singularly focused on natural products-based drug discovery and integrative medicine, bridging traditional systems (Ayurveda, Unani, Siddha) with modern pharmacology. It was originally established in 1941 as the Drug Research Laboratory of J&K State, taken over by CSIR in 1957 as the Regional Research Laboratory, Jammu, and renamed Indian Institute of Integrative Medicine in 2005 when its mandate was redefined around natural products drug discovery.

The institute runs three core research divisions — Natural Products and Medicinal Chemistry, Fermentation and Microbial Biotechnology, and Plant Sciences and Agrotechnology — supported by integrated infrastructure that includes a cGMP-compliant Pilot Plant, a NABL-accredited QC/QA division, a BSL-3 laboratory, a Fermentation Facility, an IAEC-constituted Animal House, and the Janaki Ammal Herbarium and Crude Drug Repository. Its translational pipeline spans discovery, medicinal chemistry, preclinical pharmacology, and clinical development, exemplified by the AQCH phytopharmaceutical drug candidate and the CUReD (CSIR Ushered Repurposed Drugs) clinical-trials platform. Beyond pharma R&D, CSIR-IIIM runs the Aroma Mission / Purple Revolution program for medicinal and aromatic plant cultivation (notably lavender in J&K), the IIIM-TBI technology business incubator, and an Industrial Biotech Park at Ghatti, Kathua funded by BIRAC/DBT.

CSIR-IIIM's revenue mechanics combine government / CSIR institutional funding and project-based grants (CSIR-FIRST, CSIR-RDSF, BIRAC/DBT), CSR contributions from corporates, technology licensing and out-licensing to pharma (with documented transfers such as the Favipiravir synthetic process to Cipla), fee-based NABL-accredited analytical and contract research services (Revised Price List 2024), and training and certification programs (Two-Month cGMP Certificate Course, Yuva Kaushal Karyashala 4.0, PhD via AcSIR). Its customer base spans Indian and global pharmaceutical industry, rural farmers and entrepreneurs in J&K and other Himalayan states, biotech startups, government tertiary-care hospitals, students, and the Government of Jammu & Kashmir. The institute does not disclose audited revenue figures and is fully government-owned with no private shareholders.

Name

CSIR-Indian Institute of Integrative Medicine

Legal name

CSIR - Indian Institute of Integrative Medicine (IIIM), Jammu

Website

https://iiim.res.in

Company type

Private

Founded year

1941

Operating status

Operating

Headcount range

101–250 employees

Short description

CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM) is a government-owned national research laboratory in Jammu, India, focused on natural products-based drug discovery, integrative medicine, and the Aroma Mission, serving pharma industry, farmers, startups, hospitals, and academia across India.

Ownership category

akta.pro rank

Product category

Pharmaceutical Research & Drug Discovery

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)

akta.pro primary industry

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

akta.pro secondary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Natural products drug discovery
• Pharmaceutical research services
• Medicinal chemistry research
• Herbal drug manufacturing
• Phytopharmaceutical development

Headquarters

HQ city

Jammu

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Government / CSIR institutional funding: Core funding from Council of Scientific & Industrial Research (CSIR), Ministry of Science & Technology, Government of India, plus project-based grants (CSIR-FIRST, CSIR-RDSF, CSIR-IIIM ULIP MLP002622, BIRAC/DBT Industrial Biotech Park project).
2. CSR funding from corporates for R&D: Explicit appeal on homepage inviting corporates to invest CSR funds in CSIR-IIIM R&D activities (Director CSIR-IIIM as point of contact).
3. Technology licensing and out-licensing to pharma industry: Mandate explicitly includes working with Indian and global pharmaceutical industry to out-license new products and technologies; CSIR transferred Favipiravir synthesis technology to Cipla, scaled and launched as Ciplenza.
4. Contract research and analytical/testing services: Fee-for-service NABL-accredited QC/QA testing of drugs, foods and essential oils; rate list of farms tech services published; services / business overview section on website.
5. Training programs and certificate courses (revenue from fees): Trainings section, two-month cGMP herbal drug manufacturing certificate course, Yuva Kaushal Karyashala 4.0, Research & Training Program (Summer Call), PhD programme via AcSIR.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels10 records

Core offering

CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM) is a government-owned national research laboratory conducting natural-products-based drug discovery and translational research across medicinal chemistry, plant and microbial biotechnology, fermentation technology, and phytopharmaceutical development. It delivers contract research, NABL-accredited analytical testing, cGMP-compliant herbal drug manufacturing, technology licensing to the pharmaceutical industry, agro-technology for medicinal and aromatic plants, and accredited training/certification programs.

Product overview

CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu is a national research institute under India's Council of Scientific & Industrial Research whose offering is a multi-division research-to-product platform rather than a single unified product. The platform is anchored by three core research divisions — Natural Products and Medicinal Chemistry, Fermentation and Microbial Biotechnology, and Plant Sciences and Agrotechnology — that together drive discovery of novel pharmacologically active natural products from plants and microbes and their translation into drug leads. Built on this core, CSIR-IIIM operates a set of named products and facilities: the Janaki Ammal Herbarium botanical database and the CUReD clinical-trials database for knowledge assets; the AQCH phytopharmaceutical drug candidate and the cGMP Pilot Plant for translational and manufacturing capability; the Fermentation Facility, BSL-3 laboratory, Animal House, and NABL-accredited QC/QA Division as research infrastructure; the CSIR-IIIM TBI technology business incubator and the Industrial Biotech Park at Ghatti (Kathua) for industry translation; the CSIR-IIIM Aroma Mission Phase-III (with Lavender Festival at Bhaderwah) as the agricultural/agro-product program; and licensed technologies such as Green Pigment Production Technology (jointly scaled with TERI) and aromatic-crop/essential-oils-based botanical wellness products (with Ambrosia Botanicals). Training and certification offerings such as Yuva Kaushal Karyashala 4.0 and the Two-Month Certificate Course on cGMP-Compliant Herbal Drug Manufacturing sit on top of this stack, while regulatory and quality regimes (cGMP, GAP, GLP, GCP, NABL) are applied across the platform.

Differentiator

Problem solved

Functional benefit

Products and services

• AQCH Phytopharmaceutical Drug Candidate First phytopharmaceutical drug put under CSIR-partnered clinical trial; CSIR-IIIM is among the CSIR labs driving its development through the CUReD repurposed drugs pipeline. Targeted at pharmaceutical companies and clinical research institutions.
• Janaki Ammal Herbarium (Botanical Database) Online botanical database cataloguing plant specimens across numerous families with accession metadata, place/date of collection, morphological remarks, taxonomic synonyms, and cross-references to PubMed, NCBI Taxonomy and Wiki Species. Used by medicinal chemistry researchers and the wider scientific community.
• CUReD (CSIR Ushered Repurposed Drugs) ClinicalTrials Database Public website providing information on CSIR-partnered clinical trials (Drugs/Vaccines/Therapeutics, AYUSH Prophylactics/Therapeutics, Diagnostics/Devices) and associated industry and hospital partners; central hub for CSIR's COVID-19 clinical trial pipeline.
• CSIR-IIIM Aroma Mission Phase-III (Lavender Cultivation & Essential Oils Program) Flagship program driving commercial cultivation of high-value aromatic crops (notably lavender) in Jammu & Kashmir and other Himalayan states; engaged over 5,000 farmers/young entrepreneurs with 50+ distillation units installed across the Union Territory, producing essential oils and aroma products.
• CSIR-IIIM TBI (Technology Business Incubator) CSIR-IIIM's Technology Business Incubator supporting startups and entrepreneurs to commercialize technologies developed at the Institute.
• cGMP Pilot Plant Services Current Good Manufacturing Practice (cGMP) compliant pilot plant at CSIR-IIIM supporting preclinical-to-clinical pharmaceutical development and herbal drug manufacturing on a contract basis; also supports the Institute's cGMP certificate course.
• QC/QA (NABL-accredited) Testing Services NABL-accredited Quality Control / Quality Assurance (CMC Division) at CSIR-IIIM providing certified testing of drugs, foods, essential oils and related materials on a fee-for-service basis (per Revised Price List 2024).
• Industrial Biotech Park, Ghatti (Kathua) BIRAC/DBT-funded Industrial Biotech Park at Ghatti, Kathua implemented through CSIR-IIIM as the host institute, with dedicated project-based recruitment under Advertisement No. IBTP-1/2026.
• Green Pigment Production Technology Green pigment production technology developed by CSIR-IIIM Jammu and licensed/scaled under MoU with TERI for industrial deployment.
• Two-Month Certificate Course on cGMP-Compliant Herbal Drug Manufacturing Certificate training program launched in June 2026 to build industry-ready skills in cGMP-compliant manufacturing of herbal drugs, leveraging the Institute's cGMP Pilot Plant infrastructure.
• Yuva Kaushal Karyashala 4.0 (Advanced Biotechnology Training) Hands-on training program launched in May 2026 to train young scientists in advanced biotechnology skills, hosted by CSIR-IIIM.
• CSIR-IIIM Research & Training Program (R&TP Summer Call) Research training summer program for students and researchers at CSIR-IIIM, with selection in Natural Products and Medicinal Chemistry / Chemical Sciences streams.

Quantifiable outcome

• Over 5,000 farmers and young entrepreneurs engaged in lavender cultivation under the Aroma Mission in J&K.
• +3 more outcomes

Named customers12 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

18 partnerships are on record, tiered strategic, core and flagship.

• The Energy and Resources Institute (TERI)strategicStrategic or Co-development PartnerMoU signed with CSIR-IIIM Jammu in June 2026 to scale up Green Pigment Production Technology.
• Ambrosia BotanicalsstrategicStrategic or Co-development PartnerJoined hands with CSIR-IIIM in June 2026 to work on aromatic crops and essential oils-based botanical wellness products.
• Jammu & Kashmir Entrepreneurship Development Institute (JKEDI)coreGTM or Marketing PartnerCSIR-IIIM and JKEDI inked a pact in April 2026 to boost the startup ecosystem in J&K.
• Government Medical College (GMC) KathuacoreStrategic or Co-development PartnerMoU signed with CSIR-IIIM in April 2026 to boost clinical research and healthcare innovation in J&K.
• Council of Scientific & Industrial Research (CSIR)flagshipOthersCSIR-IIIM is a national institute under CSIR, Ministry of Science & Technology, Government of India; collaborates with sister CSIR labs (CSIR-CDRI, CSIR-IICT, CSIR-IICB, CSIR-CCMB, CSIR-NAL, CSIR-IGIB, CSIR-IHBT) on joint projects including CUReD, Aroma Mission and repurposed drug programmes.
• Cipla Ltd.flagshipStrategic or Co-development PartnerIndustry partner in CSIR-IIIM's CUReD COVID-19 partnered clinical trials; received CSIR-developed Favipiravir synthetic process and launched as Ciplenza.
• Cadila PharmaceuticalscoreStrategic or Co-development PartnerIndustry partner in CSIR-IIIM's CUReD COVID-19 partnered clinical trials.
• Sun PharmacoreStrategic or Co-development PartnerIndustry partner in CSIR-IIIM's CUReD COVID-19 partnered clinical trials.
• Mylan Laboratories Ltd.coreStrategic or Co-development PartnerCSIR partnered with Mylan to identify potential COVID-19 therapies; also listed industry partner in CUReD clinical trials.
• LAXAI Life Sciences Ltd.coreStrategic or Co-development PartnerCSIR-IIIM clinical trial industry partner.
• Medizest PharmaceuticalscoreStrategic or Co-development PartnerCSIR-IIIM clinical trial industry partner.
• ClinSync Clinical ResearchcoreImplementation/ SI/ Consulting PartnerCRO listed as industry partner in CSIR-IIIM's CUReD clinical trial pipeline.
• Bharat Biotech InternationalflagshipStrategic or Co-development PartnerCSIR-CCMB and Bharat Biotech collaborated under the CSIR-NMITLI programme for inactivated coronavirus vaccine development; CSIR-IIIM participates in the wider CSIR vaccine programme.
• Syngene International Ltd.coreStrategic or Co-development PartnerIndustry partner on NGS-based SARS-CoV-2 testing — a CSIR-IIIM partner under the CUReD COVID-19 diagnostics programme.
• Illumina Inc.coreTechnology or IntegrationIndustry partner with CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) for COVIDSeq high-throughput next-generation sequencing of SARS-CoV-2; CSIR-IIIM contributes via the CSIR CUReD platform.
• Indian Council of Medical Research (ICMR)flagshipOthersICMR is referenced as a partner for CTRI clinical trial registry, COVID-19 diagnostics validation and AYUSH/COVID-19 clinical development via CSIR's CUReD platform hosted by CSIR-IIIM.
• Academy of Scientific and Innovative Research (AcSIR)coreStrategic or Co-development PartnerAcSIR is the CSIR-wide academy through which CSIR-IIIM runs its PhD programme and notifies AcSIR Bulletin for PhD Viva voce examinations.
• CSIR-IHBT PalampurcoreStrategic or Co-development PartnerDirector of CSIR-IHBT Palampur, Dr Sudesh Kumar Yadav, serves on the CSIR-IIIM Management Council; CSIR-IIIM and CSIR-IHBT collaborate on Himalayan medicinal and aromatic plants research.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• CSIR-Central Drug Research Institute (CSIR-CDRI): Sister CSIR national laboratory in Lucknow focused on drug discovery and development across multiple therapeutic areas. Shares the same parent body, similar mission, and is a co-developer with IIIM of the CUReD COVID-19 platform, making it the closest direct peer in terms of mandate and funding model.
• CSIR-Indian Institute of Chemical Technology (CSIR-IICT): Hyderabad-based sister CSIR lab and co-developer of the Favipiravir synthetic process that IIIM transferred to Cipla. Directly comparable as a chemistry-driven CSIR lab with industrial process-transfer capability and joint COVID-19 drug-discovery activities.
• CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT): Palampur-based sister CSIR lab working on Himalayan bioresources and medicinal/aromatic plants. Its Director sits on the CSIR-IIIM Management Council, and the two institutes collaborate on MAP research — a directly comparable peer by mandate and ecosystem.
• CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB): Hyderabad-based CSIR lab and joint developer of the CUReD repurposed-drugs platform and NGS-based SARS-CoV-2 testing with IIIM. Highly comparable as a CSIR life-sciences research institute with active translational and clinical-diagnostics programmes.
• Rajiv Gandhi Centre for Biotechnology (RGCB): Thiruvananthapuram-based government biotechnology institute under the Department of Biotechnology with similar drug-discovery, disease biology and clinical-diagnostics mandates. Comparable as a publicly funded Indian translational-research peer.

Broad incumbents

• National Institute of Pharmaceutical Education and Research (NIPER): Government of India institution under the Department of Pharmaceuticals focused on pharmaceutical education, research and innovation. Comparable as a public-sector peer in pharmaceutical R&D and training, although its core mandate is academic rather than industrial technology transfer.
• ICMR-National Institute of Virology (ICMR-NIV): India's apex virology research institute under ICMR, partner with IIIM on COVID-19 diagnostics and clinical validation via the CUReD platform. Comparable as a public-sector translational-research and diagnostics-validation peer with overlapping regulatory mandate.

Others

• Syngene International: Bangalore-based listed CRO offering discovery, development and manufacturing services to global pharma. Comparable as an industry-side peer in contract research, analytical testing and NGS-based SARS-CoV-2 testing — and an actual CUReD partner alongside CSIR-IIIM.
• The Energy and Resources Institute (TERI): New Delhi-based research institute and IIIM's MoU partner (June 2026) for scale-up of CSIR-IIIM's Green Pigment Production Technology. Comparable as a publicly funded Indian translational-research peer with a focus on industrial deployment of biotech processes.

Emerging players

• Dabur Research & Development Centre: R&D arm of Dabur India, one of India's largest natural / Ayurvedic products companies with its own medicinal-plant and herbal product pipeline. Comparable as a commercial peer in natural-products drug and wellness development competing for similar IP and licensing opportunities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/csiriiim
• YouTubeyoutube.com/@csir-iiim
• Facebookfacebook.com/CsirIndianInstituteOfIntegrativeMedicine
• LinkedInin.linkedin.com/company/csir-indian-institute-of-integrative-medicine

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSIR-Indian Institute of Integrative Medicine